Synthesis and in vivo evaluation of a PET radioligand for imaging the endothelin-A receptor

Nucl Med Biol. 2006 Jan;33(1):15-9. doi: 10.1016/j.nucmedbio.2005.07.012.

Abstract

The endothelin-A receptor ligand Atrasentan (ABT-627) was radiolabeled by (11)C-methylaton of the desmethyl precursor in phenolate form. In mice, the highest uptake of [(11)C]ABT-627 was in the liver, kidneys and lungs. No significant binding was observed in mouse brain or heart. PET studies in a baboon, however, showed accumulation in the myocardium and lungs with a tissue/blood equilibrium reached at 40 min postinjection. Between 35 and 75 min, the heart/blood and lung/blood ratios were 1.72 and 1.31, respectively. Pretreatment with a 0.39 mg/kg dose of unlabeled ABT-627 inhibited the uptake of the tracer by 53-54% in both the myocardium and lungs at 65 min.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Atrasentan
  • Carbon Radioisotopes
  • Feasibility Studies
  • Male
  • Metabolic Clearance Rate
  • Mice
  • Organ Specificity
  • Papio
  • Positron-Emission Tomography / methods*
  • Pyrrolidines / pharmacokinetics*
  • Radiopharmaceuticals / pharmacokinetics
  • Receptor, Endothelin A / metabolism*
  • Species Specificity
  • Tissue Distribution

Substances

  • Carbon Radioisotopes
  • Pyrrolidines
  • Radiopharmaceuticals
  • Receptor, Endothelin A
  • Atrasentan